<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cerebrospinal fluid (CSF) soluble amyloid beta-protein (sA beta) concentrations from 69 patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), 23 patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VD), and 76 non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> controls were measured by a sandwich enzyme linked immunosorbent assay using two monoclonal antibodies (4G8 and 6E10) specific for A beta </plain></SENT>
<SENT sid="1" pm="."><plain>sA beta concentrations were lower in CSF from patients with AD or VD compared to those in controls </plain></SENT>
<SENT sid="2" pm="."><plain>CSF sA beta concentrations did not correlate with the Mini-Mental State Examination scores in patients with AD </plain></SENT>
<SENT sid="3" pm="."><plain>VD patients with moderate to severe <z:hpo ids='HP_0000726'>dementia</z:hpo> had lower CSF sA beta concentrations than those with mild <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Because a considerable overlap of CSF sA beta levels existed between AD and control groups, the assay is not useful as a diagnostic test for AD </plain></SENT>
</text></document>